Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients.

Journal of thrombosis and haemostasis : JTH - 1 Jan 2010

Gurbel P A, Bliden K P, Antonino M J, Stephens G, Gretler D D, Jurek M M, Pakyz R E, Shuldiner A R, Conley P B, Tantry U S

Abstract excerpt

UNLABELLED: To study the effect of a new direct acting reversible P2Y(12) inhibitor, elinogrel (PRT060128), and the relation to cytochrome P450 (CYP) polymorphisms in patients with high platelet reactivity (HPR) on standard dual antiplatelet therapy. METHODS AND RESULTS: We studied the pharmacodynamic and pharmacokinetic effects of a single 60-mg oral dose of elinogrel in 20 of 45 previously stented stable...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Diphosphate
Share to Angioplasty, Balloon, Coronary

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Platelet Aggregation

Share to Quinazolinones

Share to Receptors, Purinergic P2

Share to Receptors, Purinergic P2Y12

Share to Stents

Share to Ticlopidine

Source

Identifiers

PMID: 19817997
DOI: 10.1111/j.1538-7836.2009.03648.x

Genes

HPR
LTA
VASP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients.PMID 19817997Read ↗

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.Semantic proximity Read ↗

P2Y12 receptor inhibitor resistance and coronary artery disease: a bench to bedside primer for cardiovascular specialists.Semantic proximity Read ↗

Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey.Semantic proximity Read ↗

High platelet reactivity and clinical outcome - fact and fiction.Semantic proximity Read ↗

High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers.Semantic proximity Read ↗

Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.Semantic proximity Read ↗

Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?Semantic proximity Read ↗

The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy.Semantic proximity Read ↗

New P2Y12 antagonists.Semantic proximity Read ↗

Long-term antiplatelet therapy: from clinical trials to clinical application.Semantic proximity Read ↗

Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial.Semantic proximity Read ↗

Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.